This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer (CONVERT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00433563
Recruitment Status : Completed
First Posted : February 12, 2007
Last Update Posted : September 8, 2022
Sponsor:
Collaborators:
Cancer Research UK
NCIC Clinical Trials Group
European Organisation for Research and Treatment of Cancer - EORTC
Spanish Lung Cancer Group
Groupe Francais De Pneumo-Cancerologie
Intergroupe Francophone de Cancerologie Thoracique
Information provided by (Responsible Party):
The Christie NHS Foundation Trust

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which schedule of radiation therapy is more effective when given together with chemotherapy in treating small cell lung cancer.

PURPOSE: This randomized phase III trial is studying two different schedules of radiation therapy to compare how well they work when given together with cisplatin and etoposide in treating patients with limited stage small cell lung cancer.


Condition or disease Intervention/treatment Phase
Lung Cancer Radiation: Once daily radiotherapy Radiation: Twice daily radiotherapy Not Applicable

Detailed Description:

OBJECTIVES:

Primary

  • Compare overall survival of patients with limited stage small cell lung cancer treated with chemoradiotherapy comprising cisplatin, etoposide, and once vs twice daily radiotherapy.

Secondary

  • Compare local progression-free survival of patients treated with these regimens.
  • Compare metastasis-free survival of patients treated with these regimens.
  • Compare the toxicity of these regimens in these patients.
  • Compare response rates in patients treated with these regimens.
  • Compare the cytotoxic dose intensity of these regimens in these patients.
  • Compare the dose intensity of two different schedules of radiotherapy in these patients.

OUTLINE: This is a multicenter, randomized, controlled study. Patients are stratified according to participating center, ECOG performance status (0-1 vs 2), and lactic dehydrogenase, sodium, and alkaline phosphatase levels. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive cisplatin IV over 2 hours on days 1-3 OR on day 1 only and etoposide IV over 45-90 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses. During course 2, patients undergo concurrent radiotherapy once daily 5 days a week for 6½ weeks (total of 33 fractions).
  • Arm II: Patients receive cisplatin and etoposide as in arm I. During courses 2 and 3, patients undergo concurrent radiotherapy twice daily 5 days a week for 3 weeks (total of 30 fractions).

In both arms, treatment continues in the absence of disease progression or unacceptable toxicity.

Beginning 3-4 weeks after completion of chemoradiotherapy, patients in both arms achieving a complete or partial response with no evidence of brain metastasis undergo prophylactic cranial irradiation once daily 5 days a week for 2 weeks (total of 10 fractions).

After completion of study treatment, patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 532 patients will be accrued for this study.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 547 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 2-Arm Randomized Controlled Trial of Concurrent Chemo-Radiotherapy Comparing Twice-Daily and Once-Daily Radiotherapy Schedules in Patients With Limited Stage Small Cell Lung Cancer (SCLC) and Good Performance Status [CONVERT]
Study Start Date : April 2008
Actual Primary Completion Date : February 2016
Actual Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Once daily radiotherapy
Once daily radiotherapy
 Radiation: Once daily radiotherapy
Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy

Radiation: Twice daily radiotherapy
Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
Active Comparator: Twice daily radiotherapy
Twice daily radiotherapy
 Radiation: Once daily radiotherapy
Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy

Radiation: Twice daily radiotherapy
Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Overall survival [ Time Frame: August 2015 ]

Secondary Outcome Measures :
  1. Local progression-free survival [ Time Frame: August 2015 ]
  2. Metastasis-free survival [ Time Frame: August 2015 ]
  3. Toxicity of treatment [ Time Frame: August 2015 ]
  4. Cytotoxic dose intensity [ Time Frame: August 2015 ]
  5. Radiotherapy dose intensity [ Time Frame: August 2015 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion/exclusion criteria:

  • Either sex, age ≥18 years
  • Performance status ECOG grade 0-1. Patients with PS 2 whose general condition is explained by obstructive/bulky disease likely to improve after the first cycle of chemotherapy can be included at the discretion of the local investigator. Patients with PS 2 as a result of comorbid conditions will be excluded.
  • Histologically or cytologically confirmed SCLC
  • No patients with mixed small-cell and non-small-cell histologic features
  • No history of previous malignancy in the last 5 years (except non melanomatous skin or in-situ cervix carcinoma). Patients with previous malignancies (except breast cancer) and in remission for at least 5 years can be included.
  • Limited stage disease (Veterans Administration Lung Cancer Study Group) ie patients whose disease can be encompassed within a radical radiation portal.
  • No pleural or pericardial effusions proven to be malignant
  • RT target volume acceptable by the local radiotherapist

  • Pulmonary function

    1. FEV1 >1 litre or 40% predicted value
    2. KCO (DLCO/VA) >40%predicted

  • Maximum of one of the following adverse biochemical factors:

    1. Serum alkaline phosphatase more than >1.5 times the upper limit of normal (ULN)
    2. Serum sodium < Lower limit of Normal
    3. Serum LDH > ULN
  • Normal serum creatinine and calculated creatinine clearance >50 ml/min. If calculated creatinine clearance is <50 ml/mn according to the Cockroft and Gault formula, an EDTA clearance should be performed

  • Adequate haematological function

    1. Neutrophils >1.5 x 109/l
    2. Platelets >100 x 109/l
  • Adequate liver function: ALT & AST <= 2.5 x ULN
  • No other previous or concomitant illness or treatment which in the opinion of the clinician will interfere with the trial treatments or comparisons
  • No prior surgical resection of the primary tumour, no prior radiotherapy for lung cancer
  • Considered fit to receive any of the trial regimens
  • Female patients must satisfy the investigator that they are not pregnant, or are not of child-bearing potential, or are using adequate contraception. Men must also use adequate contraception, as etoposide is clastogenic.
  • Patients must not be breastfeeding
  • Patient has read the patient information sheet and has signed the consent form.
  • Patients available for follow-up
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00433563


Locations
Layout table for location information
United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Sponsors and Collaborators
The Christie NHS Foundation Trust
Cancer Research UK
NCIC Clinical Trials Group
European Organisation for Research and Treatment of Cancer - EORTC
Spanish Lung Cancer Group
Groupe Francais De Pneumo-Cancerologie
Intergroupe Francophone de Cancerologie Thoracique
Investigators
Layout table for investigator information
Study Chair: Corinne Faivre-Finn, MD The Christie NHS Foundation Trust
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: The Christie NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT00433563    
Other Study ID Numbers: CDR0000531709
CHNT-CONVERT ( Other Identifier: Christie Hospital NHS Foundation Trust )
CHNT-CTAAC-CONVERT-C17052/A815 ( Other Grant/Funding Number: Cancer Research UK )
First Posted: February 12, 2007    Key Record Dates
Last Update Posted: September 8, 2022
Last Verified: September 2022
Keywords provided by The Christie NHS Foundation Trust:
limited stage small cell lung cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
 Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms